Objectives: Addition of docetaxel in the treatment regimen has shown improvement in survival of head and neck squamous cell carcinoma (HNSCC) patients. This study was conducted to evaluate the maximum tolerated dose of weekly docetaxel when combined with concurrent administration of weekly cisplatin, daily gefitinib, and radiation therapy. Materials and Methods: 21 patients with newly diagnosed HNSCC were included. Radiation therapy was planned to a dose of 66 Gy/33 fractions. Doses of cisplatin and gefitinib were kept constant at 30 mg/m2 and 250 mg respectively. Dose of weekly docetaxel started with 5 mg/m2 and escalated 5 mg/m2 up to a maximum of 20 mg/m2. Serious adverse event was defined as grade 3/4 hematological and non-hematological toxicities. Results: No hematological serious adverse events occurred at dose levels 1–3. Weekly docetaxel of 20 mg/m2 was not tolerated and caused two grade 4 neutropenia events and one grade 3 mucositis. Six patients required omission of week 3 chemotherapy. All patients tolerated treatment with grade 2 toxicities. Conclusion: The maximal tolerated dose of weekly docetaxel added to weekly cisplatin and daily gefitinib during concurrent chemoradiation is 15 mg/m2. © 2013 Elsevier B.V., All rights reserved.